http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 10 Sep 2026 11:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Zealand+Pharma+increases+its+share+capital+as+a+result+of+the+exercise+of+employee+warrants/27046893.html <p>Company announcement – No. 47 / 2026</p> <p><b>Zealand Pharma increases its share capital as a result of the exercise of employee warrants</b></p> <p><b>Copenhagen, Denmark, September 10, 2026 </b><i>– </i>Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 31,247 divided into 31,247 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under one of Zealand Pharma's http://www.streetinsider.com/Press+Releases/Zealand+Pharma+increases+its+share+capital+as+a+result+of+the+exercise+of+employee+warrants/27046893.html Thu, 10 Sep 2026 11:00:00 -0400 ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+increases+its+share+capital+as+a+result+of+the+exercise+of+employee+warrants/27046893.html <p>Company announcement – No. 47 / 2026</p> <p><b>Zealand Pharma increases its share capital as a result of the exercise of employee warrants</b></p> <p><b>Copenhagen, Denmark, September 10, 2026 </b><i>– </i>Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 31,247 divided into 31,247 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under one of Zealand Pharma's http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+increases+its+share+capital+as+a+result+of+the+exercise+of+employee+warrants/27046893.html Thu, 10 Sep 2026 11:00:00 -0400 ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+participate+in+the+Morgan+Stanley+24th+Annual+Global+Healthcare+Conference/27041185.html <p>Press release – No. 15 / 2026</p> <p><b>Zealand Pharma to participate in the Morgan Stanley 24^th Annual Global Healthcare Conference</b></p> <p><b>Copenhagen, Denmark, September 9, 2026 </b>- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Morgan Stanley 24^th Annual Global Healthcare Conference in New York on Wednesday, September 16, 2026, at 11:30am EDT (5:30pm CEST).</p> <p>A live audio webcast of the fireside chat will be available at <a href="https://www.globenewswire.com/Tracker?data=nomij3HdBWUXLH64A6h4LVTiTZkNsKZKnHl9nLBWHkAoi_4Wz8c6NjHoyk0RB2ExQqIybhhY3uEjUWNqytbmbYD0C0nvxJzX3w_MtpotbBDTWYctkvcXRD8w7GFbszzdygKPpV6mAUBZGwvD3yiYNnMmtL3TxCr7q_oe2qS5Gnpgjg9RL_gMoO_3OfTD8uNQ5xiTweTjQgTInsx9Ef6MyBnEd5rKs9smLuEEgEG3FBEUonqAzUQX9Ss1vm82xia3PE5SLnASbJyCSpTkTRO5DA==" rel="nofollow" target="_blank">https://event.webcasts.com/starthere.jsp?ei=1773811&amp;tp_key=f2cb5f5403&amp;tp_special=8</a>, and accessible through the http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+participate+in+the+Morgan+Stanley+24th+Annual+Global+Healthcare+Conference/27041185.html Wed, 09 Sep 2026 11:00:00 -0400 ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+participate+in+the+Morgan+Stanley+24th+Annual+Global+Healthcare+Conference/27041185.html <p>Press release – No. 15 / 2026</p> <p><b>Zealand Pharma to participate in the Morgan Stanley 24^th Annual Global Healthcare Conference</b></p> <p><b>Copenhagen, Denmark, September 9, 2026 </b>- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Morgan Stanley 24^th Annual Global Healthcare Conference in New York on Wednesday, September 16, 2026, at 11:30am EDT (5:30pm CEST).</p> <p>A live audio webcast of the fireside chat will be available at <a href="https://www.globenewswire.com/Tracker?data=nomij3HdBWUXLH64A6h4LVTiTZkNsKZKnHl9nLBWHkAoi_4Wz8c6NjHoyk0RB2ExQqIybhhY3uEjUWNqytbmbYD0C0nvxJzX3w_MtpotbBDTWYctkvcXRD8w7GFbszzdygKPpV6mAUBZGwvD3yiYNnMmtL3TxCr7q_oe2qS5Gnpgjg9RL_gMoO_3OfTD8uNQ5xiTweTjQgTInsx9Ef6MyBnEd5rKs9smLuEEgEG3FBEUonqAzUQX9Ss1vm82xia3PE5SLnASbJyCSpTkTRO5DA==" rel="nofollow" target="_blank">https://event.webcasts.com/starthere.jsp?ei=1773811&amp;tp_key=f2cb5f5403&amp;tp_special=8</a>, and accessible through the http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+participate+in+the+Morgan+Stanley+24th+Annual+Global+Healthcare+Conference/27041185.html Wed, 09 Sep 2026 11:00:00 -0400 ZEAL http://www.streetinsider.com/Intl+Ratings/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html <p>Barclays analyst Yihan Li downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Overweight to Equalweight with a price target of DKK330.00 (from DKK425.00).</p><p>The analyst comments: “We continue to see a long-term role of petrelintide Amylin in obesity, but see a relatively lean slate of value-inflecting potential catalysts over the next 12 months, a higher Amylin competitive bar, and less support from survodutide (GLP-1/Glucagon) given its disappointing tolerability profile. At the current share price, valuation limits further downside, leaving risk/reward balanced, in our view.</p><p>We believe petrelintide remains the core value driver, but the key de-risking event is distant. We retain c.$3bn http://www.streetinsider.com/Intl+Ratings/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html Tue, 08 Sep 2026 02:48:40 -0400 ZEAL http://www.streetinsider.com/Downgrades/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html <p>Barclays analyst Yihan Li downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Overweight to Equalweight with a price target of DKK330.00 (from DKK425.00).</p><p>The analyst comments: “We continue to see a long-term role of petrelintide Amylin in obesity, but see a relatively lean slate of value-inflecting potential catalysts over the next 12 months, a higher Amylin competitive bar, and less support from survodutide (GLP-1/Glucagon) given its disappointing tolerability profile. At the current share price, valuation limits further downside, leaving risk/reward balanced, in our view.</p><p>We believe petrelintide remains the core value driver, but the key de-risking event is distant. We retain c.$3bn http://www.streetinsider.com/Downgrades/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html Tue, 08 Sep 2026 02:48:40 -0400 ZEAL http://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html <p>Barclays analyst Yihan Li downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Overweight to Equalweight with a price target of DKK330.00 (from DKK425.00).</p><p>The analyst comments: “We continue to see a long-term role of petrelintide Amylin in obesity, but see a relatively lean slate of value-inflecting potential catalysts over the next 12 months, a higher Amylin competitive bar, and less support from survodutide (GLP-1/Glucagon) given its disappointing tolerability profile. At the current share price, valuation limits further downside, leaving risk/reward balanced, in our view.</p><p>We believe petrelintide remains the core value driver, but the key de-risking event is distant. We retain c.$3bn http://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html Tue, 08 Sep 2026 02:48:40 -0400 ZEAL http://www.streetinsider.com/Intl+Ratings/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html <p>Barclays analyst Yihan Li downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Overweight to Equalweight with a price target of DKK330.00 (from DKK425.00).</p><p>The analyst comments: “We continue to see a long-term role of petrelintide Amylin in obesity, but see a relatively lean slate of value-inflecting potential catalysts over the next 12 months, a higher Amylin competitive bar, and less support from survodutide (GLP-1/Glucagon) given its disappointing tolerability profile. At the current share price, valuation limits further downside, leaving risk/reward balanced, in our view.</p><p>We believe petrelintide remains the core value driver, but the key de-risking event is distant. We retain c.$3bn http://www.streetinsider.com/Intl+Ratings/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html Tue, 08 Sep 2026 02:48:40 -0400 ZEAL http://www.streetinsider.com/Downgrades/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html <p>Barclays analyst Yihan Li downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Overweight to Equalweight with a price target of DKK330.00 (from DKK425.00).</p><p>The analyst comments: “We continue to see a long-term role of petrelintide Amylin in obesity, but see a relatively lean slate of value-inflecting potential catalysts over the next 12 months, a higher Amylin competitive bar, and less support from survodutide (GLP-1/Glucagon) given its disappointing tolerability profile. At the current share price, valuation limits further downside, leaving risk/reward balanced, in our view.</p><p>We believe petrelintide remains the core value driver, but the key de-risking event is distant. We retain c.$3bn http://www.streetinsider.com/Downgrades/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html Tue, 08 Sep 2026 02:48:40 -0400 ZEAL http://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html <p>Barclays analyst Yihan Li downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Overweight to Equalweight with a price target of DKK330.00 (from DKK425.00).</p><p>The analyst comments: “We continue to see a long-term role of petrelintide Amylin in obesity, but see a relatively lean slate of value-inflecting potential catalysts over the next 12 months, a higher Amylin competitive bar, and less support from survodutide (GLP-1/Glucagon) given its disappointing tolerability profile. At the current share price, valuation limits further downside, leaving risk/reward balanced, in our view.</p><p>We believe petrelintide remains the core value driver, but the key de-risking event is distant. We retain c.$3bn http://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+Zealand+Pharma+AS+%28ZEAL%3ADC%29+%28ZEAL%29+to+Equalweight/27032139.html Tue, 08 Sep 2026 02:48:40 -0400 ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+36%2C+2026%29/27031777.html <p align="justify">Company announcement No. 46 / 2026</p> <p align="justify"><b>Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, September 7, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 36 (August 31 - September 4, 2026).</p> <p align="justify">The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe http://www.streetinsider.com/Press+Releases/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+36%2C+2026%29/27031777.html Mon, 07 Sep 2026 11:00:00 -0400 ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+36%2C+2026%29/27031777.html <p align="justify">Company announcement No. 46 / 2026</p> <p align="justify"><b>Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, September 7, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 36 (August 31 - September 4, 2026).</p> <p align="justify">The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+36%2C+2026%29/27031777.html Mon, 07 Sep 2026 11:00:00 -0400 ZEAL http://www.streetinsider.com/Press+Releases/Correction%3A+Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27017241.html <p align="justify">Company announcement No. 45 / 2026</p> <p align="justify"><b>Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, September 2, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby corrects information regarding the dates for the reported transactions related to its share buy-back program (the "Program") for week 35 (August 24 – August 28, 2026), initially published in company announcement no. 44 / 2026 on August 31, 2026, as the correct dates for week 35 have now http://www.streetinsider.com/Press+Releases/Correction%3A+Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27017241.html Wed, 02 Sep 2026 11:00:00 -0400 ZEAL http://www.streetinsider.com/Globe+Newswire/Correction%3A+Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27017241.html <p align="justify">Company announcement No. 45 / 2026</p> <p align="justify"><b>Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, September 2, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby corrects information regarding the dates for the reported transactions related to its share buy-back program (the "Program") for week 35 (August 24 – August 28, 2026), initially published in company announcement no. 44 / 2026 on August 31, 2026, as the correct dates for week 35 have now http://www.streetinsider.com/Globe+Newswire/Correction%3A+Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27017241.html Wed, 02 Sep 2026 11:00:00 -0400 ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27002890.html <p align="justify">Company announcement No. 44 / 2026</p> <p align="justify"><b>Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, August 31, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 35 (August 24 - August 28, 2026).</p> <p align="justify">The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe http://www.streetinsider.com/Press+Releases/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27002890.html Mon, 31 Aug 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27002890.html <p align="justify">Company announcement No. 44 / 2026</p> <p align="justify"><b>Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, August 31, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 35 (August 24 - August 28, 2026).</p> <p align="justify">The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27002890.html Mon, 31 Aug 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27002890.html <p align="justify">Company announcement No. 44 / 2026</p> <p align="justify"><b>Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, August 31, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 35 (August 24 - August 28, 2026).</p> <p align="justify">The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe http://www.streetinsider.com/Press+Releases/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27002890.html Mon, 31 Aug 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27002890.html <p align="justify">Company announcement No. 44 / 2026</p> <p align="justify"><b>Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, August 31, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 35 (August 24 - August 28, 2026).</p> <p align="justify">The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+35%2C+2026%29/27002890.html Mon, 31 Aug 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Press+Releases/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26997700.html <p>Company announcement – No. 43 / 2026</p> <p><b>Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons</b></p> <p><b>Copenhagen, Denmark, August 28, 2026 </b>– Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma&apos;s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.</p> <p>Please see the attached file(s).</p> <p><strong>About Zealand Pharma<br/></strong>Zealand Pharma A/S (Nasdaq: ZEAL) is http://www.streetinsider.com/Press+Releases/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26997700.html Fri, 28 Aug 2026 16:00:00 -0400 O.00289404 ZEAL http://www.streetinsider.com/Globe+Newswire/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26997700.html <p>Company announcement – No. 43 / 2026</p> <p><b>Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons</b></p> <p><b>Copenhagen, Denmark, August 28, 2026 </b>– Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma&apos;s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.</p> <p>Please see the attached file(s).</p> <p><strong>About Zealand Pharma<br/></strong>Zealand Pharma A/S (Nasdaq: ZEAL) is http://www.streetinsider.com/Globe+Newswire/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26997700.html Fri, 28 Aug 2026 16:00:00 -0400 O.00289404 ZEAL http://www.streetinsider.com/Press+Releases/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26997700.html <p>Company announcement – No. 43 / 2026</p> <p><b>Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons</b></p> <p><b>Copenhagen, Denmark, August 28, 2026 </b>– Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma&apos;s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.</p> <p>Please see the attached file(s).</p> <p><strong>About Zealand Pharma<br/></strong>Zealand Pharma A/S (Nasdaq: ZEAL) is http://www.streetinsider.com/Press+Releases/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26997700.html Fri, 28 Aug 2026 16:00:00 -0400 O.00289404 ZEAL http://www.streetinsider.com/Globe+Newswire/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26997700.html <p>Company announcement – No. 43 / 2026</p> <p><b>Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons</b></p> <p><b>Copenhagen, Denmark, August 28, 2026 </b>– Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma&apos;s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.</p> <p>Please see the attached file(s).</p> <p><strong>About Zealand Pharma<br/></strong>Zealand Pharma A/S (Nasdaq: ZEAL) is http://www.streetinsider.com/Globe+Newswire/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26997700.html Fri, 28 Aug 2026 16:00:00 -0400 O.00289404 ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+%E2%80%93+Notification+of+holding+of+treasury+shares/26966001.html <p>Company announcement – No. 42 / 2026</p> <p><b>Zealand Pharma – Notification of holding of treasury shares</b></p> <p><b>Copenhagen, Denmark, August 24, 2026</b> – Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports its notification pursuant to Section 31 of the Danish Capital Markets Act relating to its holding of treasury shares.</p> <p>As of 21 August 2026, the Company holds nominally 3,597,842 treasury shares, corresponding to 5.03% of the total share capital and 5.03% of the total voting rights in Zealand Pharma. In accordance with http://www.streetinsider.com/Press+Releases/Zealand+Pharma+%E2%80%93+Notification+of+holding+of+treasury+shares/26966001.html Mon, 24 Aug 2026 11:05:00 -0400 O.00289404 ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+%E2%80%93+Notification+of+holding+of+treasury+shares/26966001.html <p>Company announcement – No. 42 / 2026</p> <p><b>Zealand Pharma – Notification of holding of treasury shares</b></p> <p><b>Copenhagen, Denmark, August 24, 2026</b> – Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports its notification pursuant to Section 31 of the Danish Capital Markets Act relating to its holding of treasury shares.</p> <p>As of 21 August 2026, the Company holds nominally 3,597,842 treasury shares, corresponding to 5.03% of the total share capital and 5.03% of the total voting rights in Zealand Pharma. In accordance with http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+%E2%80%93+Notification+of+holding+of+treasury+shares/26966001.html Mon, 24 Aug 2026 11:05:00 -0400 O.00289404 ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+%E2%80%93+Notification+of+holding+of+treasury+shares/26966001.html <p>Company announcement – No. 42 / 2026</p> <p><b>Zealand Pharma – Notification of holding of treasury shares</b></p> <p><b>Copenhagen, Denmark, August 24, 2026</b> – Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports its notification pursuant to Section 31 of the Danish Capital Markets Act relating to its holding of treasury shares.</p> <p>As of 21 August 2026, the Company holds nominally 3,597,842 treasury shares, corresponding to 5.03% of the total share capital and 5.03% of the total voting rights in Zealand Pharma. In accordance with http://www.streetinsider.com/Press+Releases/Zealand+Pharma+%E2%80%93+Notification+of+holding+of+treasury+shares/26966001.html Mon, 24 Aug 2026 11:05:00 -0400 O.00289404 ZEAL